KIR2DL3
KIR2DL3 Molecule Information
Name:Killer cell immunoglobulin-like receptor 2DL3
Target Synonym:P58.2 MHC Class-I Specific NK Receptor,MHC Class I NK Cell Receptor,CD158b2 Antigen,KIR-K7b,KIR-K7c,KIR2DS5,CD158b,KIR2DL,NKAT2A,NKAT2B,GL183,NKAT,P58,Receptors, KIR2DL3,Cl-6,Killer Cell Immunoglobulin-Like Receptor Two Domains Long Cytoplasmic Tail 3,Nat
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical
KIR2DL3 Molecule Synonym Name
KIR2DL3,CD158B2,KIRCL23,NKAT2,KIR-023GB,NKAT2a,NKAT2b,NKAT-2,CD158 B2,GL183,KIR-023GB,KIR-K7b,KIR-K7c,KIRCL23,NKAT,p58
KIR2DL3 Molecule Background
Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) is also known as CD158 antigen-like family member B2, KIR-023GB, Killer inhibitory receptor cl 2-3, MHC class I NK cell receptor, NKAT2a, NKAT2b, Natural killer-associated transcript 2, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158b2 and KIR2DL3, which is a single-pass type I membrane protein and belongs to the immunoglobulin superfamily.KIR2DL3 is a receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). KIR2DL3 can inhibit the activity of NK cells thus preventing cell lysis.
KIR2DL3 References
KIR2DL3 Clinical Drug Information
Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
Lirilumab |
IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 |
Phase 2 Clinical |
Novo Nordisk A/S |
Solid tumours; Head and Neck Neoplasms; Neoplasms; Hodgkin Disease; Smoldering Multiple Myeloma; Myelodysplastic Syndromes; Multiple Myeloma; Urinary Bladder Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|